Lorlatinib/Lorlatinib Lao version

There are multiple Laotian versions of Lorlatinib/lorlatinib (Lorlatinib) on the overseas market, which fall into the category of generic drugs. Common manufacturers may include Laos Lucius Pharmaceuticals, Daxiong Pharmaceuticals, ASEAN Pharmaceuticals, United Pharmaceuticals, Element Pharmaceuticals, etc. The drugs they produce are basically the same as the original drugs in terms of drug ingredients, but there may be slight differences in specifications, manufacturers or prices.

Lorlatinib is a novel third-generation ALK inhibitor that is more potent than second-generation inhibitors in biochemical and cellular assays and has the broadest coverage of identified ALK resistance mutations. Larlatinib is designed to cross the blood-brain barrier to achieve high exposure to the central nervous system. In studies, lorlatinib showed potent antitumor activity after failure of previous ALK inhibitors (first-generation, second-generation, or both). In particular, lorlatinib had significant intracranial activity in patients with previously treated baseline central nervous system disease, including leptomeningeal disease. Due to its efficacy and safety, lorlatinib is a standard treatment option for ALK-positive patients who have failed one or more ALK inhibitors.

Lorlatinib is only available by prescription. Treatment with Lorviqua should be initiated and supervised by a physician experienced in the use of cancer medications. Before starting treatment, a patient's cancer should be tested to confirm that it has genetic changes that affect ALK.

The Laotian version of lorlatinib sold in overseas markets is available in common specifications:100mg*30 tablets, 25mg*30 tablets, etc. The price per box is about RMB 1-3,000 (the price may fluctuate due to the exchange rate), providing more patients with an affordable treatment option.